Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000759064 | SCV000888145 | pathogenic | not provided | 2018-02-14 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001251374 | SCV001426948 | likely pathogenic | Hemoglobinopathy | 2021-11-24 | criteria provided, single submitter | clinical testing | Variant summary: HBB c.292_295dupCACG (p.Val99AlafsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251394 control chromosomes. To our knowledge, no occurrence of c.292_295dupCACG in individuals affected with Hemoglobinopathy and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
Natera, |
RCV001830660 | SCV002089198 | likely pathogenic | beta Thalassemia | 2020-12-10 | no assertion criteria provided | clinical testing |